Mismatch repair protein deficiency is common in sebaceous neoplasms and suggests the importance of screening for Lynch syndrome

American Journal of Dermatopathology

Volumn 35, Issue 2, 2013, Pages 191-195

  Plocharczyk, Elizabeth F ^a   Frankel, Wendy L ^a   Hampel, Heather ^a   Peters, Sara B ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Lynch syndrome; Microsatellite instability; Mismatch repair; Muir Torre; Sebaceous

Indexed keywords

MISMATCH REPAIR PROTEIN; MISMATCH REPAIR PROTEIN PMS2; PROTEIN MLH1; PROTEIN MSH2; PROTEIN MSH6;

ARTICLE; CANCER SCREENING; CLINICAL ARTICLE; FOLLOW UP; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MISMATCH REPAIR PROTEIN DEFICIENCY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; SCREENING TEST; SEBACEOUS CARCINOMA;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DNA REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; MUTS HOMOLOG 2 PROTEIN; NEOPLASMS, MULTIPLE PRIMARY; NUCLEAR PROTEINS; SEBACEOUS GLAND NEOPLASMS;

EID: 84878909646     PISSN: 01931091     EISSN: 15330311     Source Type: Journal    
DOI: 10.1097/DAD.0b013e31825f7efe     Document Type: Article

References (32)

1. Abbas O, Mahalingam M. Cutaneous sebaceous neoplasms as markers of Muir-Torre syndrome: a diagnostic algorithm. J Cutan Pathol. 2009;36: 613-619.
2. Lynch HT, Fusaro RM, Roberts L, et al. Muir-Torre syndrome in several members of a family with a variant of the Cancer Family Syndrome. Br J Dermatol. 1985;113:295-301.
3. Schwartz RA, Goldberg DJ, Mahmood F, et al. The muir-Torre Syndrome: a disease of sebaeous and colonic neoplasms. Dermatologica. 1989;178:23-28.
4. Singh H, Schiesser R, Anand G, et al. Underdiagnosis of Lynch syndrome involves more than family history criteria. Clin Gastroenterol Hepatol. 2010;8:523-529.
5. Hall NR, Murday VA, Chapman P, et al. Genetic linkage in Muir-Torre syndrome to the same chromosomal region as cancer family syndrome. Eur J Cancer. 1994;30:180-182.
6. Hall NR, Williams MA, Newton JA, et al. Muir-Torre syndrome: a variant of the cancer family syndrome. J Med Genet. 1994;31:627-631.
7. Honchel R, Halling KC, Schaid DJ, et al. Microsatellite instability in Muir-Torre syndrome. Cancer Res. 1994;54:1159-1163.
8. Bapat B, Xia L, Madlensky L, et al. The genetic basis of Muir-Torre syndrome includes the hMLH1 locus. Am J Hum Genet. 1996;59:736-739.
9. Entius MM, Keller JJ, Drillenburg P, et al. Microsatellite instability and expression of hMLH1 and hMSH2 in sebaceous gland carcinomas as markers for Muir-Torre syndrome. Clin Cancer Res. 2000;6:1784-1789.
10. Kruse R, Ruzicka T. DNA mismatch repair and the significance of a sebaceous skin tumor for visceral cancer prevention. Trends Mol Med. 2004;10:136-141.
11. Mangold E, Pagenstecher C, Leister M, et al. A genotype-phenotype correlation in HNPCC: strong predominance of msh2 mutations in 41 patients with Muir-Torre syndrome. J Med Genet. 2004;41:567-572.
12. Peltomaki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21:1174-1179.
13. Bellizzi AM, Frankel WL. Colorectal cancer due to deficiency in DNA mismatch repair. Adv Anat Pathol. 2009;16:405-417.
14. Mojtahed A, Schrijver I, Ford JM, et al. A two-antibody mismatch repair protein immunohistochemistry screening approach for colorectal carcinomas, skin sebaceous tumors, and gynecologic tract carcinomas. Mod Pathol. 2011;24:1004-1014.
15. Morales-Burgos A, Sanchez JL, Figueroa LD, et al. MSH-2 and MLH-1 protein expression in Muir-Torre syndrome-related and sporadic sebaceous neoplasms. P R Health Sci J. 2008;27:322-327.
16. Orta L, Klimstra DS, Qin J, et al. Towards identification of hereditary DNA mismatch repair deficiency: sebaceous neoplasm warrants routine immunohistochemical screening regardless of patient's age or other clinical characteristics. Am J Surg Pathol. 2009;33:934-944.
17. Kruse R, Rutten A, Schweiger N, et al. Frequency of microsatellite instability in unselected sebaceous gland neoplasias and hyperplasias. J Invest Dermatol. 2003;120:858-864.
18. Chhibber V, Dresser K, Mahalingam M. MSH6: extending the reliability of immunohistochemistry as a screen in Muir-Torre syndrome. Mod Pathol. 2008;21:159-164.
19. Cesinaro AM, Ubiali A, Sighinolfi P, et al. Mismatch repair proteins expression and microsatellite instability in skin lesions with sebaceous differentiation: a study in different clinical subgroups with and without extracutaneous cancer. Am J Dermatopathol. 2007;29:351-358.
20. Shalin SC, Lyle S, Calonje E, et al. Sebaceous neoplasia and the Muir-Torre syndrome: important connections with clinical implications. Histopathology. 2010;56:133-147.
21. Yanaba K, Nakagawa H, Takeda Y, et al. Muir-Torre syndrome caused by partial duplication of MSH2 gene by Alu-mediated nonhomologous recombination. Br J Dermatol. 2008;158:150-156.
22. Dores GM, Curtis RE, Toro JR, et al. Incidence of cutaneous sebaceous carcinoma and risk of associated neoplasms. Cancer. 2008;113:3372-3381.
23. Ponti G, Losi L, Di Gregorio C, et al. Identification of Muir-Torre syndrome among patients with sebaceous tumors and keratoacanthomas: role of clinical features, microsatellite instability, and immunohistochemistry. Cancer. 2005;103:1018-1025.
24. Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome for patients with colorectal cancer. J Clin Oncol. 2008;26:5783-5788.
25. Smyrk TC, Watson P, Kaul K, et al. Tumor-infiltrating lymphocytes are a marker for microsatellite instability in colorectal carcinoma. Cancer. 2001;91:2417-2422.
26. Drescher KM, Sharma P, Watson P, et al. Lymphocyte recruitment into the tumor site is altered in patients with MSI-H colon cancer. Fam Cancer. 2009;8:231-239.
27. Kazakov DV, Kutzner H, Spagnolo DV, et al. Discordant architectural and cytological features in cutaneous sebaceous neoplasms - a classification dilemma: report of 5 cases. Am J Dermatopathol. 2009;31: 31-36.
28. Mathiak M, Rutten A, Mangold E, et al. Loss of DNA mismatch repair proteins in skin tumors from patients with Muir-Torre syndrome and MSH2 or MLH1 germline mutations. Am J Surg Pathol. 2002;26: 338-343.
29. Ponti G, Lossi L, Pedroni M, et al. Value of MLH1 and MSH2 mutations in the appearance of Muir-Torre syndrome phenotype in HNPCC patients presenting sebaceous gland tumors or keratoacanthomas. J Invest Dermatol. 2006;126:2302-2307.
30. Hampel H, Frankel WL, Martin E, et al. Screening for the Lynch syndrome (hereditary nonpolyposis colorectal cancer). N Engl J Med. 2005; 352:1851-1860.
31. Ingram JR, Griffiths AP, Roberts DL. All patients with sebaceous gland neoplasms should be screened for Muir-Torre syndrome. Clin Exp Dermatol. 2008;34:240-266.
32. Manonukul J, Kajornvuthidej S. Sebaceous neoplasms in Siriraj Hospital, Mahidol University: a 9-year retrospective study. J Med Assoc Thai. 2010;93:978-991.